NEW DELHI: The National Technical Advisory Group on Immunization (NTAGI) has approved the Serum Institute’s Covid-19 Covovax for the 12-17 age group. But, no decision has been taken on ...

The Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for the Novavax and Serum Institute of India (SII) Covid-19 vaccine, Covovax, in the 12-18 age group.

Now, Covovax, known abroad as Novovax, has already been cleared by the WHO and the EU. Second, according to multiple newspaper reports, there is no shortage of Covovax.

India's drug regulator in July had granted permission to Serum Institute of India (SII) for conducting a phase 2/3 trial of Covovax on children aged 2 to 17 years with certain conditions on the ...

New Delhi: The Drugs Controller General of India (DCGI) granted permission on Wednesday for conducting the phase-3 clinical trial of Covid-19 vaccine Covovax as a booster dose in adults ...